Atomoxetine, known by its brand name Strattera, is a non-stimulant medication prescribed for Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults. It works by affecting certain brain chemicals. While not intended as a weight loss drug, some individuals taking it may experience changes in their body weight, including weight loss, as a side effect. This article explores atomoxetine’s impact on weight, its potential mechanisms, and important clinical considerations.
Atomoxetine’s General Impact on Weight
Atomoxetine is not prescribed or approved for weight reduction, yet weight changes can occur in some individuals using the medication. Clinical trials and real-world observations indicate that weight loss is a reported side effect. This effect is typically modest and does not occur in all patients. For instance, some studies reported that approximately 2% of adult patients experienced weight decrease, while decreased appetite was reported in 16% of adult patients.
In children and adolescents, decreased appetite and initial weight loss are common. This weight loss often appears early in treatment and may be followed by normal weight gain over time. Long-term studies show that weight and height averages in children receiving atomoxetine can return to expected levels after a couple of years. Some individuals may experience no weight change or even a slight gain, though reported side effects often focus on loss.
Potential Mechanisms of Weight Change
Appetite suppression is a primary reason some individuals experience weight loss with atomoxetine. Decreased appetite is frequently listed among the common adverse effects. This appetite reduction can lead to a decrease in overall food intake, which, over time, can result in weight loss.
Atomoxetine works by increasing norepinephrine levels in the brain. Norepinephrine is a neurotransmitter that plays a role in regulating various bodily functions, including appetite. Increased norepinephrine can influence brain regions controlling hunger and satiety, contributing to reduced appetite. Other gastrointestinal disturbances, like nausea and vomiting, also contribute to reduced food intake and weight loss.
Clinical Use and Important Considerations
Atomoxetine is specifically indicated for the treatment of ADHD and is not approved as a weight loss medication. Using atomoxetine off-label for weight loss is not recommended due to potential risks and unestablished safety or efficacy. Individuals should never self-medicate or alter their prescribed dosage based on weight concerns.
Healthcare providers typically monitor weight and appetite when prescribing atomoxetine for ADHD. This monitoring helps manage weight changes, especially in growing children where slowed growth can occur. Any concerns about side effects, including weight fluctuations, should be discussed with a healthcare professional. Consulting a doctor before starting or stopping any medication is a safety measure.